NCT06972992

A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC47 in Combination With Semaglutide

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC47 Injection, for Subcutaneous Use in Combination With Semaglutide in Participants With Obesity

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 28 (actual)
• Sponsor: Ascletis Pharma (China) Co., Limited · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

This will be a phase I, randomized, double-blind, placebo-controlled. This study will be conducted in three periods: the screening period, the treatment period, and the follow-up period.

Conditions

• Chronic Weight Management

Interventions

Type	Name	Description
DRUG	ASC47 +Semaglutide	ASC47 single subcutaneous injection + Semaglutide QW for 4 weeks
DRUG	Placebo+Semaglutide	Placebo single subcutaneous injection + Semaglutide QW for 4 weeks

Timeline

• Start date: 2025-04-18
• Primary completion: 2025-09-22
• Completion: 2025-09-22
• First posted: 2025-05-15
• Last updated: 2025-12-18

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study